Author

Yang Lee

GlaxoSmithKline (United States)Primary ORCID profile (0000-0002-8040-3648 · 2 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Yang LeeiD2 papers · MRC Laboratory of Molecular Biology

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Anastasia Kavasakali· 1 shared Andrea BertottiiD· 1 shared Angham Al SaediiD· 1 shared Benjamin SchwartziD· 1 shared Brian T. JonesiD· 1 shared Camille FourneauxiD· 1 shared Cansu DinçeriD· 1 shared Cuthbert D. Martyr· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Anastasia Kavasakali

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

On-target mutations confer resistance to WRN helicase inhibitors in Microsatellite Unstable Cancer Cells.

Gabriele Picco, Yanhua Rao, Angham Al Saedi, Samantha J. Walker, Shriram G. Bhosle, Yang Lee, Sara F. Vieira, María Ana García-Casado, Gilberto Valdes Garcia, Kieron May, Francesco Paolo Sassi, Inigo Barrio Hernandez, Mamta Sharma, Cansu Dinçer, Theo Bell, , Mathew J. Garnett

This study identifies on-target WRN mutations as resistance mechanisms in MSI cancer cells to WRN helicase inhibitors and suggests combination therapies to prevent resistance.

bioRxiv · Dec 27, 2025 · PreprintCancer Biology